Loading patent…
AssigneeFraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
InventorsChristopher OELKRUG, Daniel Christoph WAGNER, Armin BRAUN, Christina HESSE
Estimating the term…
An antibody or an antigen-binding fragment thereof binds to an antigen of the bacterium Candidatus savagella and inhibits the adhesion of the bacterium to intestinal epithelial cells; and/or depletes the bacterium. A drug has the antibody or an antigen-binding fragment thereof. A kit has the antibody or an antigen-binding fragment thereof for reduction of Th17 cell proliferation, Th17 cell differentiation or Th17 cell activity and/or inhibition of the formation of antibodies against endogenous antigens by B cells. The kit can contain an antibiotic. A method for producing the antibody involves immunizing chickens with an immunogenic peptide from an antigen of the bacterium Candidatus savagella, and recovering and purifying the antibodies formed in the chickens or in an egg laid by said chickens. A method for producing the drug involves producing the antibody or an antigen-binding fragment thereof, and formulating the antibody or an antigen-binding fragment thereof as a drug.
An antibody or an antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment is configured to bind to an antigen of the bacterium Candidatus savagella and (i) inhibits the adhesion of the bacterium to intestinal epithelial cells, preferably human intestinal epithelial cells, and/or (ii) depletes the bacterium.
Dependencies are inferred from the claim text.